Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Celera, AMDeC Deal Makes CDS Available to Large Number of Users

This story has been updated from a previous version.

NEW YORK, March 1 - Celera Genomics said Thursday it penned a multi-year agreement with AMDeC, a consortium of 37 New York-based medical schools and institutions, to make the Celera Discovery System available to researchers at member organizations.

Under the terms of the agreement, researchers who work for AMDeC’s affiliates will be entitled to subscribe to Celera’s database at pre-negotiated rates, Doug Sansted, general counsel for AMDeC, told GenomeWeb. The more users who subscribe, the lower the rate falls.

“We get a cheaper rate and our price is dependent on the number of users,” Sansted said. “Every researcher who is affiliated with any AMDeC member can access Celera’s data under this agreement.”

A Celera spokeswoman declined to offer any details on the terms of the deal with AMDeC, but she noted that academic subscribers generally pay between $7,000 and $15,000 a year per scientist for a subscription.

Stansted said that a number AMDeC reseachers had already subscribed to the database and that there was "widespread interest." The Celera spokeswoman said that there are potentially 1,000 individual users who could take part of the deal.

Last year, AMDeC signed a similar deal with Affymetrix. Sansted said that that deal, which offered “extremely discounted rates” for Affy’s tools, proved very successful for the researchers AMDeC represents and Affy.

In January, Celera signed on the University of California system as a subscriber to its genome database.  

Members of AMDeC, which stands for Academic Medicine Development Company, work together to develop basic science and clinical research projects. The participants include Rockefeller University, Cold Spring Harbor Laboratory, and Columbia University College of Physicians and Surgeons.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.